my aunt was just put on trastuzumab deruxtecan (Enhertu) for HER2-low breast cancer, what does HER2-low actually mean an

I am sorry to hear about your aunt’s diagnosis, but it is helpful that she has a targeted treatment plan. Understanding these terms can make the process feel a little less overwhelming.

What is HER2-low?

In breast cancer, "HER2" stands for human epidermal growth factor receptor 2. This is a protein that sits on the surface of breast cells and, when overexpressed, can cause cancer cells to grow and divide more rapidly.

• HER2-Positive: These cancers have a high level of the HER2 protein, usually because of a gene mutation.
• HER2-Negative: These cancers have very little to no HER2 protein.
• HER2-Low: This is a newer classification. It describes cancers that are technically "HER2-negative" by traditional, strict diagnostic standards, but still have a small, detectable amount of the HER2 protein on the cell surface. Previously, these patients were treated only with standard hormonal or chemotherapy, but recent research has shown that drugs like Enhertu can target these cells even at these lower levels.

How is Enhertu different from Herceptin?

Both drugs target the HER2 protein, but they work in fundamentally different ways:

Herceptin (Trastuzumab):

• Mechanism: Herceptin is a "monoclonal antibody." It acts like a guided missile that attaches itself to the HER2 protein on the surface of the cancer cell. By doing this, it blocks the protein from receiving growth signals and also alerts the body’s immune system to destroy the cell.
• Limitations: It generally only works well if the cancer has high levels of HER2. It is not designed to penetrate the cell itself.

Enhertu (Trastuzumab deruxtecan):

• Mechanism: Enhertu is an "antibody-drug conjugate" (often called a "Trojan horse" drug). It consists of three parts:
  1. An antibody (similar to the one in Herceptin) that finds the HER2 protein.
  2. A potent chemotherapy agent (the cargo).
  3. A linker that keeps the chemotherapy attached to the antibody until it enters the cell.
• The Difference: Because Enhertu carries its own chemotherapy "payload" directly into the cell, it is much more effective at killing cells that have only small amounts of HER2. Once the antibody latches onto the HER2 protein, the entire complex is pulled into the cell, where the linker breaks and releases the chemotherapy directly inside, destroying the cancer cell from the inside out.

In short, while Herceptin essentially "tags" the outside of the cell to stop it from growing, Enhertu uses the HER2 protein as a doorway to deliver a powerful dose of chemotherapy directly into the cancer cell.

If you have specific concerns about your aunt’s treatment plan or potential side effects, her oncology team is the best resource, as they can provide context specific to her overall health and medical history.